Thanks, Peter. There's a couple of updates that we would like to discuss with respect to capital activity.
First, with respect to our distribution policy, let's turn to Slide 21. In March, our Board of Directors declared our distributions for Q2 of $0.083 per share per month. In our earnings release, we reported that we generated $0.32 per share in NII, which covers our distribution by approximately 1.3x. Last Friday, we announced our distribution for Q3, continuing to distribute at the level from Q1 and Q2 of $0.083 per share per month or approximately 7.3% of our March 31 NAV. We intend to augment this base distribution with special distributions from NII generated in excess of the declared distribution and as catalyst-driven investments are realized over time.
Next, with respect to our stock buyback program, let's turn to Slide 22. During Q1, we purchased nearly 246,000 shares of our stock through our 10b5-1 program at an average discount to our March 31 NAV of 16%, utilizing the $2.8 million of our $15 million 10b5-1 program. Rolling that forward, to Q2 to date through May 10, 2017, we have purchased over 378,000 shares cumulatively at a weighted average discount to our March 31 NAV of 18%.
In aggregate, we have used approximately $4.2 million of cash to date under our 10b5-1 program, where we have systematically bought shares in the open market as they traded below 90% of NAV. The discounted purchases to date represent expected accretion to NAV of approximately $0.09 per share since the inception of the program.
In addition to the authorized $15 million 10b5-1 program, our Board of Directors authorized $35 million in share repurchase capacity, which we view as further evidence of our intense focus on alignment of interest with our stockholders.
Lastly, with respect a stock buyback activity, our $10 million self-tender offer expired on May 5 and we announced the final results last week. In the tender, we purchased nearly 870,000 shares, representing approximately 6.9% of our outstanding shares at a price of $11.50 per share on a pro rata basis for a total cost of approximately $10 million before fees and expenses. This purchase price represented approximately 85% of our March 31 NAV and adds an expected $0.14 per share of potential NAV accretion.
With that capital activity update, let me turn the call back over to Peter for closing remarks and then Q&A.